Micro-scale assessment of bone quality changes in adult cadaveric men with congestive hepatopathy.
Bone quality
Congestive hepatopathy
Connexin 43
Lumbar vertebrae
Osteocytes
Sclerostin
Journal
Histochemistry and cell biology
ISSN: 1432-119X
Titre abrégé: Histochem Cell Biol
Pays: Germany
ID NLM: 9506663
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
accepted:
13
06
2022
pubmed:
19
7
2022
medline:
15
12
2022
entrez:
18
7
2022
Statut:
ppublish
Résumé
Congestive hepatopathy (CH) is a chronic liver disease (CLD) caused by impaired hepatic venous blood outflow, most frequently resulting from congestive heart failure. Although it is known that heart failure and CLDs contribute to increased risk for age-related fractures, an assessment of CH-induced skeletal alterations has not been made to date. The aim of our study was to characterize changes in bone quality in adult male cadavers with pathohistologically confirmed CH compared with controls without liver disease. The anterior mid-transverse part of the fifth lumbar vertebral body was collected from 33 adult male cadavers (age range 43-89 years), divided into the CH group (n = 15) and the control group (n = 18). We evaluated trabecular and cortical micro-architecture and bone mineral content (using micro-computed tomography), bone mechanical competence (using Vickers micro-hardness tester), vertebral cellular indices (osteocyte lacunar network and bone marrow adiposity), and osteocytic sclerostin and connexin 43 expression levels (using immunohistochemistry staining and analysis). Deterioration in trabecular micro-architecture, reduced trabecular and cortical mineral content, and decreased Vickers microhardness were noted in the CH group (p < 0.05). Reduced total number of osteocytes and declined connexin 43 expression levels (p < 0.05) implied that harmed mechanotransduction throughout the osteocyte network might be present in CH. Moreover, elevated expression levels of sclerostin by osteocytes could indicate the role of sclerostin in mediating low bone formation in individuals with CH. Taken together, these micro-scale bone alterations suggest that vertebral strength could be compromised in men with CH, implying that vertebral fracture risk assessment and subsequent therapy may need to be considered in these patients. However, further research is required to confirm the clinical relevance of our findings.
Identifiants
pubmed: 35849203
doi: 10.1007/s00418-022-02128-7
pii: 10.1007/s00418-022-02128-7
doi:
Substances chimiques
Connexin 43
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
583-593Subventions
Organisme : Science Fund of the Republic of Serbia
ID : 7749444
Organisme : Alexander von Humboldt-Stiftung
ID : 3.4-1162414-SRB-IP
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Balasubramaniyan V, Dhar DK, Warner AE et al (2013) Importance of connexin-43 based gap junction in cirrhosis and acute-on-chronic liver failure. J Hepatol 58:1194–1200. https://doi.org/10.1016/j.jhep.2013.01.023
doi: 10.1016/j.jhep.2013.01.023
Boivin G, Bala Y, Doublier A et al (2008) The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patients. Bone 43:532–538. https://doi.org/10.1016/j.bone.2008.05.024
doi: 10.1016/j.bone.2008.05.024
Bonewald LF, Johnson ML (2008) Osteocytes, mechanosensing and Wnt signaling. Bone 42:606–615. https://doi.org/10.1016/j.bone.2007.12.224
doi: 10.1016/j.bone.2007.12.224
Bouxsein ML, Boyd SK, Christiansen BA et al (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25:1468–1486. https://doi.org/10.1002/jbmr.141
doi: 10.1002/jbmr.141
Chang YC, Hsu BG, Liou HH et al (2018) Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients. BMC Cardiovasc Disord 18:1–8. https://doi.org/10.1186/s12872-018-0955-5
doi: 10.1186/s12872-018-0955-5
Chen TL, Lin CS, Shih CC et al (2017) Risk and adverse outcomes of fractures in patients with liver cirrhosis: two nationwide retrospective cohort studies. BMJ Open 7:1–10. https://doi.org/10.1136/bmjopen-2017-017342
doi: 10.1136/bmjopen-2017-017342
Cooreman A, van Campenhout R, Yanguas SC et al (2020) Cholestasis differentially affects liver connexins. Int J Mol Sci 21:6534. https://doi.org/10.3390/ijms21186534
doi: 10.3390/ijms21186534
Culafić D, Djonic D, Culafic-Vojinovic V et al (2014) Evidence of degraded BMD and geometry at the proximal femora in male patients with alcoholic liver cirrhosis. Osteoporos Int 26:253–259. https://doi.org/10.1007/s00198-014-2849-4
doi: 10.1007/s00198-014-2849-4
Davis HM, Aref MW, Aguilar-Perez A et al (2018) Cx43 overexpression in osteocytes prevents osteocyte apoptosis and preserves cortical bone quality in aging mice. JBMR Plus 2:206–216. https://doi.org/10.1002/jbm4.10035
doi: 10.1002/jbm4.10035
De Maré A, Verhulst A, Cavalier E et al (2019) Clinical inference of serum and bone sclerostin levels in patients with end-stage kidney disease. J Clin Med 8:2027. https://doi.org/10.3390/jcm8122027
doi: 10.3390/jcm8122027
Di Iorgi N, Mittelman SD, Gilsanz V (2008) Differential effect of marrow adiposity and visceral and subcutaneous fat on cardiovascular risk in young, healthy adults. Int J Obes 32:1854–1860. https://doi.org/10.1038/ijo.2008.170
doi: 10.1038/ijo.2008.170
Djonić D, Milovanović P, Djurić M (2013) Basis of bone strength vs. bone fragility: a review of determinants of age-related hip fracture risk. Srp Arh Celok Lek 141:548–552. https://doi.org/10.2298/SARH1308548D
doi: 10.2298/SARH1308548D
Ehnert S, Aspera-Werz RH, Ruoß M et al (2019) Hepatic osteodystrophy-molecular mechanisms proposed to favor its development. Int J Mol Sci. https://doi.org/10.3390/ijms20102555
doi: 10.3390/ijms20102555
Frost RJA, Sonne C, Wehr U, Stempfle HU (2007) Effects of calcium supplementation on bone loss and fractures in congestive heart failure. Eur J Endocrinol 156:309–314. https://doi.org/10.1530/EJE-06-0614
doi: 10.1530/EJE-06-0614
Ghosh M, Majumdar SR (2014) Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis. Endocrine 46:397–405. https://doi.org/10.1007/s12020-014-0167-4
doi: 10.1007/s12020-014-0167-4
Giallourakis CC, Rosenberg PM, Friedman LS (2002) The liver in heart failure. Clin Liver Dis 6:947–967. https://doi.org/10.1016/S1089-3261(02)00056-9
doi: 10.1016/S1089-3261(02)00056-9
Hasic D, Lorbeer R, Bertheau RC et al (2020) Vertebral bone marrow fat is independently associated to vat but not to sat: Kora FF4—whole-body mr imaging in a population-based cohort. Nutrients 12:1–10. https://doi.org/10.3390/nu12051527
doi: 10.3390/nu12051527
Hay E, Bouaziz W, Funck-Brentano T, Cohen-Solal M (2016) Sclerostin and bone aging: a mini-review. Gerontology 62:618–623. https://doi.org/10.1159/000446278
doi: 10.1159/000446278
Hernández-Guerra M, Hadjihambi A, Jalan R (2019) Gap junctions in liver disease: implications for pathogenesis and therapy. J Hepatol 70:759–772. https://doi.org/10.1016/j.jhep.2018.12.023
doi: 10.1016/j.jhep.2018.12.023
Jadzic J, Cvetkovic D, Tomanovic N et al (2020) The severity of hepatic disorder is related to vertebral microstructure deterioration in cadaveric donors with liver cirrhosis. Microsc Res Tech. https://doi.org/10.1002/jemt.23642
doi: 10.1002/jemt.23642
Jadzic J, Milovanovic P, Cvetkovic D et al (2021) Mechano-structural alteration in proximal femora of individuals with alcoholic liver disease: Implications for increased bone fragility. Bone 150:116020. https://doi.org/10.1016/j.bone.2021.116020
doi: 10.1016/j.bone.2021.116020
Jadzic J, Milovanovic PD, Cvetkovic D et al (2022) The altered osteocytic expression of connexin 43 and sclerostin in human cadaveric donors with alcoholic liver cirrhosis: potential treatment targets. J Anat. https://doi.org/10.1111/joa.13621
doi: 10.1111/joa.13621
Jandl NM, Rolvien T, Schmidt T et al (2020) Impaired bone microarchitecture in patients with hereditary hemochromatosis and skeletal complications. Calcif Tissue Int 106:465–475. https://doi.org/10.1007/s00223-020-00658-7
doi: 10.1007/s00223-020-00658-7
Kostin S, Dammer S, Hein S et al (2004) Connexin 43 expression and distribution in compensated and decompensated cardiac hypertrophy in patients with aortic stenosis. Cardiovasc Res 62:426–436. https://doi.org/10.1016/j.cardiores.2003.12.010
doi: 10.1016/j.cardiores.2003.12.010
Liang J, Meng WD, Yang JM et al (2018) The association between liver cirrhosis and fracture risk: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 89:408–413. https://doi.org/10.1111/cen.13762
doi: 10.1111/cen.13762
Loncar G, Cvetinovic N, Lainscak M et al (2020) Bone in heart failure. J Cachexia Sarcopenia Muscle. https://doi.org/10.1002/jcsm.12516
doi: 10.1002/jcsm.12516
Lyons KJ, Majumdar SR, Ezekowitz JA (2011) The unrecognized burden of osteoporosis-related vertebral fractures in patients with heart failure. Circ Heart Fail 4:419–424. https://doi.org/10.1161/CIRCHEARTFAILURE.111.961185
doi: 10.1161/CIRCHEARTFAILURE.111.961185
Milovanovic P, Busse B (2019) Inter-site variability of the human osteocyte lacunar network: implications for bone quality. Curr Osteoporos Rep 17:105–115. https://doi.org/10.1007/s11914-019-00508-y
doi: 10.1007/s11914-019-00508-y
Moschen AR, Kaser A, Stadlmann S et al (2005) The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 43:973–983. https://doi.org/10.1016/j.jhep.2005.05.034
doi: 10.1016/j.jhep.2005.05.034
Myers RP, Cerini R, Sayegh R et al (2003) Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology 37:393–400. https://doi.org/10.1053/jhep.2003.50062
doi: 10.1053/jhep.2003.50062
Novo-Rodríguez C, García-Fontana B, der Dios Luna-Del Castillo J et al (2018) Circulating levels of sclerostin are associated with cardiovascular mortality. PLoS One 13:1–14. https://doi.org/10.1371/journal.pone.0199504
doi: 10.1371/journal.pone.0199504
Plotkin LI, Bellido T (2013) Beyond gap junctions: connexin43 and bone cell signaling. Bone 52:157–166. https://doi.org/10.1016/j.bone.2012.09.030
doi: 10.1016/j.bone.2012.09.030
Schmidt T, Schmidt C, Schmidt FN et al (2018) Disease duration and stage influence bone microstructure in patients with primary biliary cholangitis. J Bone Miner Res 33:1011–1019. https://doi.org/10.1002/jbmr.3410
doi: 10.1002/jbmr.3410
Schmidt T, Schwinge D, Rolvien T et al (2019) Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis. J Hepatol 70:941–953. https://doi.org/10.1016/j.jhep.2018.12.035
doi: 10.1016/j.jhep.2018.12.035
Schwartz AV (2015) Marrow fat and bone: Review of clinical findings. Front Endocrinol (Lausanne) 6:1–6. https://doi.org/10.3389/fendo.2015.00040
doi: 10.3389/fendo.2015.00040
Stains JP, Fontana F, Civitelli R (2019) Chapter 18—Intercellular junctions and cell–cell communication in the skeletal system. In: Bilezikian J, Martin T John, Clemens T, Rosen C (eds) Principles of bone biology. Amsterdam, Elsevier Inc., pp 423-442
Van Diepen S, Majumdar SR, Bakal JA et al (2008) Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16 294 patients. Circulation 118:1946–1952. https://doi.org/10.1161/CIRCULATIONAHA.108.784009
doi: 10.1161/CIRCULATIONAHA.108.784009
Wakolbinger R, Muschitz C, Scheriau G et al (2019) Bone microarchitecture and bone turnover in hepatic cirrhosis. Osteoporos Int 30:1195–1204. https://doi.org/10.1007/s00198-019-04870-6
doi: 10.1007/s00198-019-04870-6
Wakolbinger R, Muschitz C, Wallwitz J et al (2020) Serum levels of sclerostin reflect altered bone microarchitecture in patients with hepatic cirrhosis. Wien Klin Wochenschr 132:19–26. https://doi.org/10.1007/s00508-019-01595-8
doi: 10.1007/s00508-019-01595-8
Wells ML, Venkatesh SK (2018) Congestive hepatopathy. Abdom Radiol 43:2037–2051. https://doi.org/10.1007/s00261-017-1387-x
doi: 10.1007/s00261-017-1387-x
Wells ML, Fenstad ER, Poterucha JT et al (2016) Imaging findings of congestive hepatopathy. Radiographics 36:1024–1037. https://doi.org/10.1148/rg.2016150207
doi: 10.1148/rg.2016150207
Wölfel EM, Jähn-rickert K, Schmidt FN et al (2020) Individuals with type 2 diabetes mellitus show dimorphic and heterogeneous patterns of loss in femoral bone quality. Bone 140:115556. https://doi.org/10.1016/j.bone.2020.115556
doi: 10.1016/j.bone.2020.115556
Xanthopoulos A, Starling RC, Kitai T, Triposkiadis F (2019) Heart failure and liver disease: cardiohepatic interactions. JACC Heart Fail 7:87–97. https://doi.org/10.1016/j.jchf.2018.10.007
doi: 10.1016/j.jchf.2018.10.007
Xing W, Lv X, Gao W et al (2018) Bone mineral density in patients with chronic heart failure: a meta-analysis. Clin Interv Aging 13:343–353. https://doi.org/10.2147/CIA.S154356
doi: 10.2147/CIA.S154356
Yanguas SC, Willebrords J, Maes M et al (2016) Connexins and pannexins in liver damage. EXCLI J 15:177–186. https://doi.org/10.17179/excli2016-119
doi: 10.17179/excli2016-119
Yousry WA, Hussein MM, Mohse MM et al (2016) Value of serum sclerostin in osteopenia and osteoporosis associated with liver cirrhosis and post liver transplantation. IOSR J Dent Med Sci 15:59–64. https://doi.org/10.9790/0853-1508065964
doi: 10.9790/0853-1508065964
Zimmermann EA, Fiedler IAK, Busse B (2021) Breaking new ground in mineralized tissue: assessing tissue quality in clinical and laboratory studies. J Mech Behav Biomed Mater. https://doi.org/10.1016/j.jmbbm.2020.104138
doi: 10.1016/j.jmbbm.2020.104138